Alligator Bioscience AB (publ)
ATORX
Rank in Stocks
#33296
Alligator Bioscience AB (publ) is a research-intensive biotechnology company... Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its drug development. These include ALLIGATOR-GOLD and ALLIGATOR-FAB, an extensive human antibody library boasting roughly 60 billion distinct antibody fragments; FIND, a molecular evolution technique used for optimizing antibodies and other proteins; and RUBY, a specialized format for creating bispecific antibodies. Alligator Bioscience's pipeline features several promising candidates. In the clinical stage, Mitazalimab, an immunostimulatory CD40 antibody, has successfully completed Phase I trials for metastatic cancer. Also undergoing Phase I clinical evaluation is ATOR-1017, another immunostimulatory antibody designed to bind to the 4-1BB receptor on tumor-specific T cells. For its preclinical efforts, the company is advancing ALG.APV-527, a bispecific antibody targeting both 4-1BB and 5T4 for cancer therapy. Additionally, Alligator Bioscience holds an interest in the Biosynergy (AC101) project, which is currently in Phase I. To bolster its research and development capabilities, Alligator Bioscience has formed multiple strategic collaborations. It has a co-development partnership with Aptevo Therapeutics Inc. for ALG.APV-527, and a research alliance with MacroGenics, Inc. to create novel immunotherapies. Further collaborations include a joint research agreement with BioArctic AB (publ) to utilize proprietary antibody generation technologies for new product candidates, and a research and license agreement with Orion Corporation aimed at discovering and developing new bispecific antibody cancer therapeutics. The company was established in 2000.
Share Price
$0.00099292
Last synced: 2026-11-11
Market Cap
$623.66K
Change (1 day)
-1.70%
Change (1 year)
-99.08%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Alligator Bioscience AB (publ) (ATORX)
Category
Healthcare
Operating Margin for Alligator Bioscience AB (publ) (ATORX)
Operating Margin as of November 2026 TTM: -34,256.89%
According to Alligator Bioscience AB (publ)'s latest financial reports, its current operating margin (TTM) is -34,256.89%. At the end of 2025 the company had an operating margin of -23,780.54%.
Operating Margin history for Alligator Bioscience AB (publ) from 2014 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -34,256.89% | 44.05% |
| 2025 | -23,780.54% | 5,895.19% |
| 2024 | -396.66% | -7.43% |
| 2023 | -428.49% | -20.66% |
| 2022 | -540.09% | -50.62% |
| 2021 | -1,093.76% | -67.01% |
| 2020 | -3,315.67% | -32.64% |
| 2019 | -4,922.42% | 766.88% |
| 2018 | -567.83% | 418.38% |
| 2017 | -109.54% | 13.76% |
| 2016 | -96.29% | -237.46% |
| 2015 | 70.05% | -101.12% |
| 2014 | -6,257.13% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -100.00% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Alligator Bioscience AB (publ)'s operating margin
What is Alligator Bioscience AB (publ)'s operating margin?
Alligator Bioscience AB (publ)'s operating margin is -34,256.89%, as of Nov 2026.
What was Alligator Bioscience AB (publ)'s operating margin in 2025?
In 2025, Alligator Bioscience AB (publ)'s operating margin was -23,780.54%, compared with -396.66% in 2024.
How has Alligator Bioscience AB (publ)'s operating margin changed since 2020?
From 2020 to 2025, Alligator Bioscience AB (publ)'s operating margin was highest in 2024 (-396.66%) and lowest in 2025 (-23,780.54%).
How does Alligator Bioscience AB (publ)'s operating margin compare with similar companies?
Alligator Bioscience AB (publ)'s operating margin (-34,256.89%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.